Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral theophylline for cardiac syndrome X
IRCT20260619069872N1Phase 3Recruiting
- Sponsor
- Alborz University of Medical Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Coronary Small Vessel Disease (CMD) and microvascular angina (MVA) comparing Theophylline with Placebo (2 arms). Primary endpoints: Change in Seattle Angina Questionnaire physical limitation score, Change in Seattle Angina Questionnaire angina stability score and 3 more. Started Jul 2026; status: recruiting.
02
Drugs
theophylline
03
Conditions
Coronary Small Vessel Disease (CMD)microvascular angina (MVA)
Beyond the preview
Go deeper on IRCT20260619069872N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260619069872N1.